CSL Faces Shareholder Class Action Over Profit Forecasts
CSL has been sued in a shareholder class action alleging it misled investors by maintaining earnings forecasts despite knowing, or having reason to know, that problems in its blood plasma-derived therapies...To view the full article, register now.
Already a subscriber? Click here to view full article